On This Page

Filter

These are the filters currently being used to limit the search results. Click on the
icon to remove the filter.

min answer › question first answered

2019-05-20T16:40:23.527Z

answer › answering member constituency

Thurrock

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are
shown at the top of the list. Click on to remove a sort and or to reverse the current sort order. Click on the icon to remove all the sorting. Note that sorting can significantly slow down the
loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined
views, but starred properties are always present no matter what the view. You can
star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

To ask the Secretary of State for Health and Social Care, how many families are in
receipt of Healthy Start vouchers in (a) Barnsley Central, (b) Sheffield City Region
Mayoral Combined Authority and (c) Yorkshire and the Humber region.

<p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United
Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s
routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro
and Priorix have been evaluated before they were given a Marketing Authorisation in
Europe, and the Marketing Authorisation Holder for each vaccines is legally required
to submit periodic safety update reports to the regulator, which are documents intended
to provide an evaluation of the risk-benefit balance of a medicinal product at defined
time points after its authorisation. The sites at which the products are manufactured
are also required to undergo periodic inspections to ensure that they comply with
Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines
control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s
testing. These procedures ensure that the MMR vaccines available in the UK are safe
and efficacious and that the manufacturers/Marketing Authorisation holders are held
accountable for their products.</p><p>A European Public Assessment Report (EPAR) for
M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf"
target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix
was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro
contains a general summary of the manufacturing information that was provided during
the assessment process; however, the specific details of the manufacturing process
are confidential.</p>

<p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella
(MMR) vaccine remains under continual review by the Medicines and Healthcare products
Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance,
including regular review of suspected adverse reactions submitted through the Yellow
Card Scheme, data from clinical and epidemiological studies, the medical literature
and information from pharmaceutical companies and other worldwide regulatory authorities.
The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal
performance in monitoring the safety of vaccines and medicines.</p><p>The balance
of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p>

<p>Currently there are no restrictions that limit the administration of dermal fillers
on young people under the age of 18 years old.</p><p>The Department is exploring options
to introduce age restrictions on access to cosmetic procedures, bringing them in line
with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020
all dermal fillers, irrespective of their composition and intended use, will be regulated
as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745).
The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The
Government is committed to improving the safety of cosmetic procedures through better
training for practitioners, and clear information so that people can make informed
decisions about their care. The growth in non-surgical treatments increases the need
for consumer protection and we are currently working with stakeholders to strengthen
the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure
to take the time to find a reputable, insured and appropriately qualified practitioner
who is either subject to statutory regulation or on a voluntary register accredited
by the Professional Standards Authority.</p>

<p>Public Health England (PHE) works to reduce the incidence of sudden infant death
syndrome.</p><p>PHE does this through the provision of professional leadership and
guidance to the health visiting profession such as PHE’s Early Years High Impact Area
five - Managing minor illnesses and reducing accidents, to improve outcomes for all
children and prevent avoidable deaths. This can be viewed at the following link:</p><p><a
href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/756697/early_years_high_impact_area_5.pdf"
target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/756697/early_years_high_impact_area_5.pdf</a></p><p>The
Start4Life programme provides information on safe sleeping and sepsis through its
Information Service for Parents email programme and the Start4Life website. Information
leaflets, posters and social media toolkits are available to general practitioners,
hospitals, children’s centres and local authorities. Start for life and the campaign
resources can be viewed at the following links:</p><p><a href="https://www.nhs.uk/start4life"
target="_blank">https://www.nhs.uk/start4life</a></p><p><a href="https://campaignresources.phe.gov.uk/resources/campaigns/2-start4life/resources"
target="_blank">https://campaignresources.phe.gov.uk/resources/campaigns/2-start4life/resources</a></p><p>PHE
also works with the Lullaby Trust such as Safer Sleep Week, co-produced fact sheets
for parents and professionals on safer sleep spaces to promote safer choices. This
can be viewed at the following link:</p><p><a href="https://www.lullabytrust.org.uk/wp-content/uploads/Facts-and-Figures-for-2015-released-2017.pdf"
target="_blank">https://www.lullabytrust.org.uk/wp-content/uploads/Facts-and-Figures-for-2015-released-2017.pdf</a></p>

To ask the Secretary of State for Health and Social Care, what assessment he has made
of the implications for his policies of the MBRRACE-UK maternal deaths and morbidity
statistics 2014-16 showing that (a) Asian women are nearly twice as likely, (b) mixed
race women are twice as likely and (c) black women are five times as likely to die
during or up to six weeks after pregnancy than white women.

<p>The NHS Long Term Plan takes a concerted and systematic approach to reducing health
inequalities and addressing unwarranted variation in care. NHS England and NHS Improvement
are leading the work through the Maternity Transformation Programme to support maternity
services to provide high-quality maternity care for all women.</p><p>Targeted and
enhanced continuity of carer can significantly improve outcomes for women from ethnic
minorities. The NHS Long Term plan sets out that 75% of black women will receive continuity
of carer from midwives by 2024.</p><p>The Department is also funding research to investigate
the factors associated with the excess perinatal mortality experienced by black/black
British and Asian/Asian British ethnic groups and identify the factors associated
with the excess risk of maternal death for black and South Asian women.</p>

<p>In prison, patients presenting with problematic psychoactive substance use are
assessed in the same way as other drug users and offered an appropriate range of psychosocial
interventions.</p><p>In April 2018, NHS England and NHS Improvement published its
updated service specification on ‘Integrated Substance Misuse Treatment Service in
Prisons in England’. This is fully aligned to ‘Drug Misuse and Dependence: UK Guidelines
on Clinical Management’, which sets out how clinicians should treat people with drug
misuse and drug dependence problems.</p><p>The service specification describes a fully
recovery orientated, integrated prison substance misuse treatment service, which covers
traditional drugs of abuse, psychoactive substances (including synthetic cannabis),
illicit abuse of prescribed and over the counter drugs and alcohol.</p><p>This improved
substance misuse service offer is now being commissioned across all prisons and secures
integration with mental health services so that growing numbers of people in prisons
can access services to support their recovery and wellbeing.</p>

To ask the Secretary of State for Health and Social Care, what recent assessment he
has made of the (a) availability and (b) waiting times for therapeutic services for
mental health conditions in Nottinghamshire.

<p>Information on the availability of therapeutic services for mental health conditions
delivered through the Improving Access to Psychological Therapies (IAPT) programme
in Nottinghamshire clinical commissioning groups (CCGs)<sup>1</sup> is not collected.</p><p>Information
on waiting times for such services in the Nottinghamshire CCGs in 2019 is in the following
table.</p><table><tbody><tr><td><p>Month</p></td><td><p>Number of referrals finishing
a course of treatment</p></td><td><p>Mean wait to enter treatment<sup>2</sup> (days)</p></td><td><p>Percentage
of finishing referrals<sup>3</sup> seen within 6 weeks</p></td></tr><tr><td><p>January
2019</p></td><td><p>1,345</p></td><td><p>24.3</p></td><td><p>83</p></td></tr><tr><td><p>February
2019</p></td><td><p>1,290</p></td><td><p>24.8</p></td><td><p>81</p></td></tr><tr><td><p>March
2019</p></td><td><p>1,510</p></td><td><p>25.3</p></td><td><p>79</p></td></tr><tr><td><p>April
2019</p></td><td><p>1,280</p></td><td><p>27.4</p></td><td><p>76</p></td></tr></tbody></table><p>Source:
NHS Digital, IAPT dataset</p><p>Notes:</p><p><sup>1</sup> NHS Bassetlaw CCG, NHS Mansfield
and Ashfield CCG, NHS Newark and Sherwood CCG, NHS Nottingham City CCG, NHS Nottingham
North and East CCG, NHS Nottingham West CCG and NHS Rushcliffe CCG.</p><p><sup>2</sup>
Waiting time to enter treatment is calculated as the number of days between the referral
received date and the first attended treatment appointment. Referral received date
and the first treatment appointment dates do not necessarily occur in the same month.</p><p><sup>3</sup>
In order to finish a course of treatment, a referral must have ended in the month
with at least two treatment appointments having been attended in the course of the
referral.</p>

To ask the Secretary of State for Health and Social Care, what assessment he has made
of the effect of reductions in public health funding on the health and wellbeing of
the most marginalised people in the UK.

<p>Public health services can have a significant impact in improving the health of
the population and reducing unfair differences between marginalised groups of people
or communities.</p><p>The Government has made difficult choices to protect public
services in the long term. We remain committed to securing five extra years of healthy,
independent life by 2035 and reducing the gap between rich and poor with proposals
set out in the Prevention Green Paper and a Long Term Plan for the National Health
Service with a greater focus on prevention. We want everyone to have the same opportunity
to have a long healthy life, whoever they are and whatever their social circumstances.</p>

<p>Public health services can have a significant impact in improving the health of
the population and reducing unfair differences between marginalised groups of people
or communities.</p><p>The Government has made difficult choices to protect public
services in the long term. We remain committed to securing five extra years of healthy,
independent life by 2035 and reducing the gap between rich and poor with proposals
set out in the Prevention Green Paper and a Long Term Plan for the National Health
Service with a greater focus on prevention. We want everyone to have the same opportunity
to have a long healthy life, whoever they are and whatever their social circumstances.</p>